536 related articles for article (PubMed ID: 17689411)
1. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study.
Saidi S; Slamia LB; Mahjoub T; Ammou SB; Almawi WY
J Stroke Cerebrovasc Dis; 2007; 16(4):153-9. PubMed ID: 17689411
[TBL] [Abstract][Full Text] [Related]
2. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T
Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406
[TBL] [Abstract][Full Text] [Related]
3. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss.
Magdoud K; Herbepin VG; Touraine R; Almawi WY; Mahjoub T
Am J Reprod Immunol; 2013 Sep; 70(3):246-52. PubMed ID: 23521508
[TBL] [Abstract][Full Text] [Related]
5. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic gene polymorphism and ischemic stroke.
Jood K; Ladenvall P; Tjärnlund-Wolf A; Ladenvall C; Andersson M; Nilsson S; Blomstrand C; Jern C
Stroke; 2005 Oct; 36(10):2077-81. PubMed ID: 16179568
[TBL] [Abstract][Full Text] [Related]
7. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.
Wiklund PG; Nilsson L; Ardnor SN; Eriksson P; Johansson L; Stegmayr B; Hamsten A; Holmberg D; Asplund K
Stroke; 2005 Aug; 36(8):1661-5. PubMed ID: 16020771
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic variants of fibrinolytic system with stroke and stroke subtypes.
Babu MS; Prabha TS; Kaul S; Al-Hazzani A; Shafi G; Roy S; Balakrishna N; Jyothy A; Munshi A
Gene; 2012 Mar; 495(1):76-80. PubMed ID: 22240314
[TBL] [Abstract][Full Text] [Related]
10. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
Emingil G; Berdeli A; Gürkan A; Han Saygan B; Köse T; Atilla G
J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
[TBL] [Abstract][Full Text] [Related]
11. The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis.
Attia J; Thakkinstian A; Wang Y; Lincz L; Parsons M; Sturm J; McGettigan P; Scott R; Meldrum C; Levi C
J Stroke Cerebrovasc Dis; 2007; 16(4):173-9. PubMed ID: 17689414
[TBL] [Abstract][Full Text] [Related]
12. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
13. A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease.
Adamski MG; Turaj W; Slowik A; Wloch-Kopec D; Wolkow P; Szczudlik A
Acta Neurol Scand; 2009 Aug; 120(2):94-100. PubMed ID: 19154538
[TBL] [Abstract][Full Text] [Related]
14. Allele-specific transcription of the PAI-1 gene in human astrocytes.
Hultman K; Tjarnlund-Wolf A; Odeberg J; Eriksson P; Jern C
Thromb Haemost; 2010 Nov; 104(5):998-1008. PubMed ID: 20806116
[TBL] [Abstract][Full Text] [Related]
15. An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke.
Boncoraglio GB; Bodini A; Brambilla C; Carriero MR; Ciusani E; Parati EA
Cerebrovasc Dis; 2006; 22(2-3):191-5. PubMed ID: 16735791
[TBL] [Abstract][Full Text] [Related]
16. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
[TBL] [Abstract][Full Text] [Related]
17. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
18. Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis.
Gürkan A; Emingil G; Saygan BH; Cinarcik S; Atilla G; Köse T; Berdeli A
J Periodontol; 2007 Jul; 78(7):1256-63. PubMed ID: 17608581
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
Ding J; Nicklas BJ; Fallin MD; de Rekeneire N; Kritchevsky SB; Pahor M; Rodondi N; Li R; Zmuda JM; Harris TB
Am Heart J; 2006 Dec; 152(6):1109-15. PubMed ID: 17161063
[TBL] [Abstract][Full Text] [Related]
20. A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes.
Yenilmez C; Ozdemir Koroglu Z; Kurt H; Yanas M; Colak E; Degirmenci I; Gunes HV
J Clin Pharm Ther; 2017 Feb; 42(1):103-107. PubMed ID: 27796029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
